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EXPERIMENTAL STUDIES ON THE RADIOPROTECTIVE EFFECT 
OF THE PREPARATION PHASEOLOSAXIN
The finding of effective radioprotectors is one of the most pressing and as - 
yet unsolved problems in radiobioiogy.
The earliest investigations on the radioprotective effect of phytohemagg­
lutinin (PHA) date back to 1963, when Schrek and Stefani published the 
results of their experiments, carried out on peripheral human blood lym­
phocytes, treated with nitrogen mustards (HN2) and X-Tays (21), in vitro. 
More recent studies, made by the same authors (23), verified the original 
results on richer experimental material and moreover demonstrated that 
PHA, applied on leucocyte cultures of peripheral human blood, exhibits 
a more pronounced radioprotective effect than that observed with cys- 
steine (22).
We studied the influence of PHA upon Vitia faba (26) with the aim to 
find out up to what extent is the radioprotective effect of PHA specifically 
manifested merely toward human lymphocytes in vitro, or else, it represents 
a general biologic phenomenon. It is well known that the plant just men­
tioned is characterized by a high degree radiosensibility (2), on account 
of which Tank recommends it as a pattern for primary selection of radio- 
protective compounds (8).
In the present work we employed the preparation Phaseolosaxin (PHA of 
Phaseolus vulgaris) 0,85% NaCl solution. The plants are subjected to 
the PHA action an hour prior to irradiation by submerging their roots into 
PHA solution for 60-minute duration. Three different PHA concentrations 
are tested: 1,5 mg %, 3 mg % and 10 mg %. In the control group, the 
plants are treated with NaCl solution in concentration correspoding to 
that of the PHA. Irradiation is carried out a single time, using three dif­
ferent X-ray doses: 200 r, 300 r and 400 r.
The daily (24-hour) growth of the roots of the experimental group is 
followed up, considering it as an index of the radioprotective effect of PHA 
in relation to the growth in the controls, recorded up to the tenth post­
irradiation day.
An optimal radioprotective effect is likewise established in plants treated 
with 3 mg % Phaseolosaxin and irradiated with 300 r. In the plants thus 
treated the root growth is restored as early as the third-fourth day after 
irradiation, secondary roots occur between the second and fourth day (on 
the 7th day for the controls) and the green part displays noticeable haste­
ning of development as compared with unprotected plants. A rather weakly 
manifested radioprotective effect is observed in plants undergoing treat­
ment with 1,5 mg % and 10 mg % PHA concentrations (26).
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The circumstance that PHA of Phaseolus vulgaris is a radioprotector 
both for peripheral human blood leukocytes (21, 22) and for growing orga­
nisms warrants the assumption that the phenomenon discussed is of general 
biological significance. The latter fact encouraged the authors to proceed 
with further investigations in this field.
In the experimental study described, we make an attempt to follow up 
the radioprotective action exerted by PHA upon animal organisms.
Material and method
The radioprotective effect of Phaseolosaxin preparation is tested on a 
series of 60 sexually mature white mice, weighing 20 gr in the average 
(40 male and 20 female), divided into five groups. The groups are uniformly 
composed — each comprising 12 mice (8 male and 4 female).
Intraperitoneal application of PHA is performed at a dose 10 mg per kg 
body weight (0,2 ml per animal with 1 mg ml concentration of the solution). 
In two of the groups Phaseolosaxin is applied respectively 10 min and one 
hour prior to irradiation, and in the other two — in the same intervals 
after the irradiation. One group of irradiated but untreated with PHA 
mice is left for control purposes.
Radiation is carried out a single time with apparatus Rontgen-Bombe 
„Siemens“ with the following technical data: tension 180 kV, 10 mA, fil­
ter 1 mm Cu, focus-to-object distance 40 cm, air dose capacity 16,1 r/min, 
dose 800 r.*
The listed below indices are considered in assessing the radioprotective 
effect of PHA: 1) survival of the animals up to the 30th day after irradia­
tion, 2) average life span of the dead animals, 3) clinical manifestations 
(apetite, body w'eight, diarrhea, hemorrhages, swelling of paws and muzzle).
Results and discussion
The results of the investigation are illustrated in tabie№ 1 and diagram № 1.
It is^vident from the table that the average life-span of the mice, protec­
ted with PHA prior to irradiation (group one and two), considerably exceeds 
that of the control animals. The percentage of survivals up to the 30th post 
irradiation day is the highest in the second group (50%), next ranking 
group one (25%) against 17% in the control group.
The first fatal outcome in the control group is recorded on the 4th day 
after irradiation and up to the sixth day, four animals in all die against 
a nil mortality rate in group one and a single death in group tw'o for the same 
period (see diagram 1).
In the animals protected with PHA before irradiation, the clinical ma­
nifestations of acute radiation disease are rather mildly pronounced and 
more promptly overcomed as compared to controls. The optimal protective 
effect is observed in the animals of group two, showing a rapid weight gain
1 We wish to express our deep gratitude to assistant professor D. Popmihayiov. 
At. D., head of the chair of Roentgenology, and to L Obreshkova, laboratory assistant . 
for the valuable aid rendered us during experimentation
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in shortest terms without edemata and displaying a stronger vitality than 
unprotected mice.
PHA application after irradiation does not protect the animals from de­
veloping acute radiation disease in its full severity (see data in table 1 for 
groups three and four).
Fig. I. Survival of the animals of the experimental and control groups up to 
the 30th day after irrradiation, expressed in absolute values. Along 
the absciss days of observation after the irradiation; along the ordinate-
number of animals
The reliability of difference between the average life-span in the experi­
mental groups and the control group, checked up to the 30th day after 
irradiation, is verified by the t — criterium. In this case p 0,01 corresponds 
to t >  2,98. In the experiment described, PHA exert statistically signifi­
cant radioprotective effect in the animals of group tw'o merely, for which 
t =  3,77 (p >  0,01).
The results of the experiment show' that PHA, applied in mice mtra- 
peritoneally (in a determined concentration), 10 min prior to irradiation 
with sublethal X-ray doses, exerts statistically reliable radioprotective 
effect.
The mechanism of the radioprotective action of PHA has sparked a great 
surge of interest. The amino acids cystine and glutamic acid (10), which 
are known to possess a proved radioprotective effect (1, 9), enter in the 
composition of PHA. In all likelihood, the PHA interferes with cellular 
metabolism at the DNA (deribonucleinic acid) — synthesis level. Irradiation 
lowers DNA synthesis with about 40 -50 per cent, whereas the stimulating 
effect of PHA upon the DNA-svnthesis (17. 18) and RNA (27) in vitro, 
is long since established.
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We found out that PHA (preparation Phaseolosaxin) represents a mosaic 
of 12 antigens (24). Many authors (3, 4, 6, 7) lay emphasis on the radiopro­
tective action exerted by antigens of different origin.
PHA, applied intravenously in humans, accounts for a rise of hematolo­
gical tolerance during anticancer chemotherapy (15, 16). Such data are in 
accordance with the results claimed by Robinson (20) and Humble (14) 
for the stimulation of medullary regeneration under the effect of PHA.
Tabl e  1
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14,6 ±  7,25
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10,6 ±  6,3
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33,4 50 83,4 2 16.7
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11.8 ±  4,8
12,3 ±  3,8
6.8 ±  2,7






10,8 ±  6,35
13,2 ±  7,8 
7,3 ±  2,1
33,4 50 83,4 2 16,7
Personal investigations (12, 25) as well as studies made by other authors 
(Humble, Israel) indicate that PHA represents a non-specific stimulator 
of immunologic processes within the organism.
More recently, the radioprotective effect of PHA is investigated under 
various conditions and methods of application by a great number of authors. 
This explains the contradictory results thus far obtained. For example, 
Papac (19) applies PHA-M „Difco“ in large doses, one-two hours after irra­
diation of rats with sublethal X-ray doses without establishing any radio­
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protective effect. In addition, under the experimental setting described, 
the author observes a toxic PHA action. The results reported by Papac 
are in agreement with our previous investigations (11) upon the effect of 
large PHA doses, applied to rabbits intravenously. The negative result 
insofar radioprotective effect of PHA is concerned, is obviously due to its 
delayed application — a circumstance noted in the present experiment as 
well (in groups three and four). Besides that, in the experiment herein des­
cribed PHA-P (pure protein) is employed, whereas Papac resorted to PHA-M 
(mucoprotein). It is furthermore assumed, that the mucin group enhances 
the toxic effect of PHA and therefore this type of preparation appears to 
be inadequate for similar experimentation. On the other hand, the intra- 
peritoneal application, used by the authors, has an advantage over the 
intravenous insofar avoiding of anaphylactic phenomena is concerned. The 
inferences reached are likewise in agreement with the experimental data 
reported by Robinson, who gives a similar interpretation of the superiority 
of the intraperitoneal over the intravenous application of PHA and empha­
sizes the importance of the time of application of the drug in view of secu­
ring its radioprotective effect (20).
The investigations of Elves (13) also demonstrate the absence of toxicity 
in the action of PHA when introduced into rats, in small doses, intraperito- 
neally or subcutaneously.
The data presented on the radioprotective properties of PHA, applied in 
animal organisms, have the characteristics of a preliminary report. But 
even though assumed as preliminary, they are significant prognosticalwise 
insofar application of phytohemagglutinin as radioprotector is concerned and 
will surely be extended and intensified in further experimental works.
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O РАДИОЗАЩИТНОМ ДЕЙСТВИИ ПРЕПАРАТА PHASEOLOSAXIN
M. T. Цонева-Маневи, Е Г. Вошнакоеа
РЕЗЮМЕ
Исследовано радиозащитное действие препарата Phaseolosaxin (ФХА 
фитогемоагглютинин из Phaseolus vulgaris) на полово зрелнх белих 
мншах. ФХА, примененннй внутрибрюшинно в дозе 10 мг кг веса 
(0,2 мл на животное, при концентрации раствора в 1 мг/мл), за 10 минут 
до облучения сублетальной дозой рентгеновских лучей (800 г), оказн- 
вает существенннй радиозащитннй зффект. В виде количественного 
показателя зффекта, ФХА прослеживается леталитет животннх до 30-го 
дня после облучения.
Полученнне результатн согласуются с данньши прошлнх исследова- 
ний авторов, в целях установления радиозащитного зффекта ФХА при 
растительннх видах.
Автори объясняют радиозащитнне свойства исследуемого препарата, 
его стимул и рующим действием на метаболизм клеток и на восстанови- 
тельнне процесси в организме.
